Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing denifanstat (TVB-2640), a selective fatty acid synthase (FASN) inhibitor targeting metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and metabolic dysfunction-associated steatotic liver disease (MASLD). The company is pre-revenue with a Phase 2b FASCINATE-2 trial ongoing, positioning it as a speculative play on the large unmet need in liver disease treatment. Stock performance is driven entirely by clinical trial readouts, regulatory milestones, and cash runway visibility given the $200M market cap and negative operating cash flow.
Sagimet operates a classic biotech development model: raise capital through equity offerings, deploy funds into clinical trials to generate proof-of-concept data, then either commercialize independently or partner/license assets to larger pharma companies. The FASN inhibitor mechanism targets lipid metabolism in the liver, differentiating from GLP-1 agonists and other MASH therapies. Monetization depends entirely on successful Phase 3 trials and FDA approval, likely 2028-2030 timeline. Current 13.04x current ratio suggests approximately 2-3 years of cash runway at current burn rate, critical for reaching value-inflection clinical milestones without dilutive financing.
FASCINATE-2 Phase 2b trial data readouts for denifanstat in MASH patients (primary endpoints: liver fat reduction, fibrosis improvement)
FDA regulatory feedback on Phase 3 trial design and approvability pathway for MASH indication
Cash position updates and equity financing announcements (dilution risk given negative FCF)
Competitive clinical data from rival MASH programs (Madrigal's resmetirom approved March 2024, Akero, Viking, others)
Partnership or licensing deal announcements that validate denifanstat's commercial potential
Clinical trial failure risk: Phase 2b/3 trials have 30-40% historical success rates in MASH; negative efficacy or safety data would likely eliminate most equity value
Competitive obsolescence: Madrigal's resmetirom already approved (March 2024), GLP-1 agonists showing liver benefits, creating high bar for denifanstat differentiation
Regulatory pathway uncertainty: FDA MASH approval requirements evolving; potential for endpoint changes or additional trial requirements extending timeline 2+ years
Reimbursement risk: Payer willingness to cover MASH therapies at premium pricing remains unproven given large patient population and budget impact
Madrigal (resmetirom), Akero (efruxifermin), Viking (VK2809) have advanced clinical programs with potential earlier market entry
GLP-1 receptor agonists (Novo Nordisk, Eli Lilly) demonstrating MASH benefits as secondary endpoints, potentially commoditizing the market
Large pharma in-house MASH programs may reduce partnership appetite for denifanstat if mechanism redundancy exists
Equity dilution risk: Negative $25M+ annual FCF requires future capital raises; at $200M market cap, meaningful dilution likely before commercialization
Cash runway constraints: Estimated 2-3 year runway may be insufficient to reach Phase 3 readout without interim financing, creating forced-sale risk in adverse markets
No debt cushion: While 0.00 D/E eliminates solvency risk, also means no non-dilutive financing flexibility if equity markets close
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital as risk appetite for speculative biotech declines, (2) partnership deal valuations as pharma companies conserve cash, (3) patient enrollment if economic stress affects healthcare access. MASH prevalence correlates with obesity/metabolic syndrome, which has weak cyclical sensitivity.
Rising interest rates negatively impact Sagimet through multiple channels: (1) higher discount rates compress NPV of distant future cash flows (approval/commercialization 3-5+ years out), making long-duration biotech assets less attractive, (2) risk-free rate competition reduces appetite for speculative growth stocks, (3) increased cost of capital for future debt financing if needed. The 1.5x P/B ratio suggests modest valuation premium despite negative earnings, vulnerable to rate-driven multiple compression. Clinical-stage biotechs typically underperform in rising rate environments as investors rotate to profitable, cash-generative businesses.
Minimal direct credit exposure given zero debt (0.00 D/E ratio) and no commercial operations requiring trade credit. However, credit market conditions indirectly affect: (1) biotech sector equity valuations and ability to raise growth capital, (2) potential acquirers' financing capacity for M&A, (3) partnership deal structures if pharma partners face credit constraints. The 13.04x current ratio provides substantial liquidity buffer, reducing near-term refinancing risk.
growth/speculative - Attracts biotech-focused investors seeking asymmetric risk/reward from binary clinical catalysts. The 47% 1-year return despite -24% 6-month return reflects high volatility around news flow. Negative margins and zero revenue eliminate value and dividend investors. Requires high risk tolerance and willingness to underwrite 3-5 year development timelines with substantial failure probability. Typical holders: biotech hedge funds, venture crossover funds, retail speculators.
high - Clinical-stage biotechs exhibit 60-100%+ annualized volatility driven by binary trial outcomes. The -15% 3-month, -24% 6-month, +47% 1-year returns demonstrate extreme dispersion. Single-asset companies like Sagimet face existential risk from negative Phase 2b/3 data, creating potential for 50-80% single-day declines. Conversely, positive data can drive 100-300% rallies. Implied volatility typically 80-120% ahead of major data readouts.
